The hormonal receptor status in breast cancer can be altered by neoadjuvant chemotherapy: A meta-analysis

Cancer Investigation

Volumn 29, Issue 9, 2011, Pages 594-598

  Zhang, Ning ^a   Moran, Meena S ^b   Huo, Qiang ^a   Haffty, Bruce G ^c   Yang, Qifeng ^a  

^a SHANDONG UNIVERSITY   (China)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

Author keywords

Breast cancer; Estrogen receptor; Meta analysis; Neoadjuvant chemotherapy; Progesterone receptor

Indexed keywords

BIOLOGICAL MARKER; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; HORMONE RECEPTOR; KI 67 ANTIGEN; PROGESTERONE RECEPTOR;

ADJUVANT CHEMOTHERAPY; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; DEXTRAN CHARCOAL; HUMAN; IMMUNOASSAY; IMMUNOHISTOCHEMISTRY; META ANALYSIS; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; RECEPTOR DOWN REGULATION; RECEPTOR UPREGULATION; SOLID PHASE MONOCLONAL IMMUNOASSAY; THERAPY EFFECT;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; FEMALE; HUMANS; NEOADJUVANT THERAPY; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE;

EID: 80054857691     PISSN: 07357907     EISSN: 15324192     Source Type: Journal    
DOI: 10.3109/07357907.2011.621913     Document Type: Article

References (22)

1. De Lena M, Zucali R, Viganotti G, Valagussa P, Bonadonna G. Combined chemotherapy-radiotherapy approach in locally advanced (t3b-t4) breast cancer. Cancer Chemother Pharmacol 1978;1:53-59. (Pubitemid 9025112)
2. Burcombe RJ, Makris A, Richman PI, Daley FM, Noble S, Pittam M, Wright D, Allen SA, Dove J, Wilson GD. Evaluation of er, pgr, her-2 and ki-67 as predictors of response to neoadjuvant anthracycline chemotherapy for operable breast cancer. Br J Cancer 2005;92:147-155. (Pubitemid 40188448)
3. Precht LM, Lowe KA, Atwood M, Beatty JD. Neoadjuvant chemotherapy of breast cancer: Tumor markers as predictors of pathologic response, recurrence, and survival. Breast J 2010;16:362-368.
4. TanMC, AlMushawah F, Gao F, Aft RL, Gillanders WE, Eberlein TJ,Margenthaler JA. Predictors of complete pathological response after neoadjuvant systemic therapy for breast cancer. Am J Surg 2009;198:520-525.
5. Caudle AS, Gonzalez-Angulo AM, Hunt KK, Liu P, Pusztai L, Symmans WF, Kuerer HM, Mittendorf EA, Hortobagyi GN, Meric-Bernstam F. Predictors of tumor progression during neoadjuvant chemotherapy in breast cancer. J Clin Oncol 2010;28:1821-1828.
6. Lee SH, Chung MA, Quddus MR, Steinhoff MM, Cady B. The effect of neoadjuvant chemotherapy on estrogen and progesterone receptor expression and hormone receptor status in breast cancer. Am J Surg 2003;186:348-350.
7. Makris A, Powles TJ, Allred DC, Ashley SE, Trott PA, Ormerod MG, Titley JC, Dowsett M. Quantitative changes in cytological molecular markers during primary medical treatment of breast cancer: A pilot study. Breast Cancer Res Treat 1999;53:51-59. (Pubitemid 29123619)
8. Arens N, Bleyl U, Hildenbrand R. Her2/neu, p53, ki67, and hormone receptors do not change during neoadjuvant chemotherapy in breast cancer. Virchows Arch 2005;446:489-496. (Pubitemid 40884281)
9. Lee J, Im YH, Lee SH, Cho EY, Choi YL, Ko YH, Kim JH, Nam SJ, KimHJ,Ahn JS,ParkYS, LimHY,HanBK, Yang JH.Evaluationof er and ki-67 proliferation index as prognostic factors for survival following neoadjuvant chemotherapy with doxorubicin/docetaxel for locally advanced breast cancer. Cancer Chemother Pharmacol 2008;61:569-577.
10. Liedtke C, Broglio K, Moulder S, Hsu L, Kau SW, Symmans WF, Albarracin C, Meric-Bernstam F, Woodward W, Theriault RL, Kiesel L, Hortobagyi GN, Pusztai L, Gonzalez-Angulo AM. Prognostic impact of discordance between triple-receptor measurements in primary and recurrent breast cancer. Ann Oncol 2009;20:1953-1958.
11. Simmons C,Miller N, GeddieW, Gianfelice D, Oldfield M, Dranitsaris G, Clemons MJ. Does confirmatory tumor biopsy alter the management of breast cancer patients with distant metastases? Ann Oncol 2009;20:1499-1504.
12. Amir E, Clemons M. Should a biopsy be recommended to confirm metastatic disease in women with breast cancer? Lancet Oncol 2009;10:933-935.
13. Karlsson E, Lindström LS, Wilking U, Skoog L, Johansson U, Bergh J. Discordance in hormone receptor status in breast cancer during tumor progression [Abstract]. J Clin Oncol 2010: 1009.
14. Kasami M, Uematsu T, Honda M, Yabuzaki T, Sanuki J, Uchida Y, Sugimura H. Comparison of estrogen receptor, progesterone receptor and her-2 status in breast cancer pre- and post-neoadjuvant chemotherapy. Breast 2008;17:523-527.
15. Morris DM, Edwards J, Gelder F. Hormonal receptors in locally advanced breast cancer: Change with response to neoadjuvant chemotherapy? J Surg Oncol 1991;46:156-158.
16. Lo SS, Wang HC, Shyr YM, Lui WY. Can the hormonal receptor status of primary breast cancer be altered by neoadjuvant chemotherapy? J Surg Oncol 1994;57:94-96.
17. Jain V, Landry M, Levine EA. The stability of estrogen and progesterone receptors in patients receiving preoperative chemotherapy for locally advanced breast carcinoma. Am Surg 1996;62:162-165. (Pubitemid 26162285)
18. Faneyte IF, Schrama JG, Peterse JL, Remijnse PL, Rodenhuis S, van de Vijver MJ. Breast cancer response to neoadjuvant chemotherapy: Predictive markers and relation with outcome. Br J Cancer 2003;88:406-412. (Pubitemid 36308152)
19. Taucher S, Rudas M, Gnant M, Thomanek K, Dubsky P, Roka S, Bachleitner T, Kandioler D, Wenzel C, Steger G, Mittlbock M, Jakesz R. Sequential steroid hormone receptor measurements in primary breast cancer with and without intervening primary chemotherapy. Endocrine-Related Cancer 2003;10:91-98. (Pubitemid 36457240)
20. Piper GL, Patel NA, Patel JA, Malay MB, Julian TB. Neoadjuvant chemotherapy for locally advanced breast cancer results in alterations in preoperative tumor marker status. Am Surg 2004;70:1103-1106.
21. Rody A, Karn T, Gatje R, Kourtis K, Minckwitz G, Loibl S, Munnes M, Ruckhaberle E, Holtrich U, Kaufmann M, Ahr A. Gene expression profiles of breast cancer obtained from core cut biopsies before neoadjuvant docetaxel, adriamycin, and cyclophoshamide chemotherapy correlate with routine prognostic markers and could be used to identify predictive signatures. Zentralbl Gynakol 2006;128:76-81.
22. Hirata T, Shimizu C, Yonemori K, Hirakawa A, Kouno T, Tamura K, Ando M, Katsumata N, Fujiwara Y. Change in the hormone receptor status following administration of neoadjuvant chemotherapy and its impact on the long-term outcome in patients with primary breast cancer. Br J Cancer 2009;101:1529-1536.